Literature DB >> 10652232

Regulatory roles for CD14 and phosphatidylinositol in the signaling via toll-like receptor 4-MD-2.

S Akashi1, H Ogata, F Kirikae, T Kirikae, K Kawasaki, M Nishijima, R Shimazu, Y Nagai, K Fukudome, M Kimoto, K Miyake.   

Abstract

The complex consisting of Toll-like receptor 4 (TLR4) and associated MD-2 signals the presence of lipopolysaccharide (LPS) when it is expressed in cell lines. We here show that normal human mononuclear cells express TLR4 and signal LPS via TLR4. CD14 is a molecule that binds to LPS and facilitates its signaling. Little is known, however, about the relationship of CD14 with TLR4-MD-2. We show that CD14 helps TLR4-MD-2 to sense and signal the presence of LPS. CD14 has also been implicated in recognition of apoptotic cells, which leads to phagocytosis without activation. Membrane phospholipids such as phosphatidylserine (PS) or phosphatidylinositol (PtdIns) are thought to serve as the ligands for CD14 in apoptotic cells. We find that PtdIns acts as an LPS antagonist in the signaling via TLR4-MD-2. TLR4-MD-2 seems to discriminate LPS from phospholipids. The signaling via TLR4-MD-2 is thus regulated by CD14 and phospholipid such as PtdIns. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10652232     DOI: 10.1006/bbrc.2000.2089

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  29 in total

Review 1.  Toll receptors: a central element in innate immune responses.

Authors:  Thierry Vasselon; Patricia A Detmers
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

2.  Immunomodulatory effects of Yersinia pestis lipopolysaccharides on human macrophages.

Authors:  Motohiro Matsuura; Hideyuki Takahashi; Haruo Watanabe; Shinji Saito; Kazuyoshi Kawahara
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

3.  The Fas-associated death domain protein suppresses activation of NF-kappa B by LPS and IL-1 beta.

Authors:  Douglas D Bannerman; Joan C Tupper; James D Kelly; Robert K Winn; John M Harlan
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

4.  Antibody Cross-Linking of CD14 Activates MerTK and Promotes Human Macrophage Clearance of Apoptotic Neutrophils: the Dual Role of CD14 at the Crossroads Between M1 and M2c Polarization.

Authors:  Gaetano Zizzo; Philip L Cohen
Journal:  Inflammation       Date:  2018-12       Impact factor: 4.092

5.  Ionizing radiation stimulates secretion of pro-inflammatory cytokines: dose-response relationship, mechanisms and implications.

Authors:  Yu-Xing Shan; Shun-Zi Jin; Xiao-Dong Liu; Yang Liu; Shu-Zheng Liu
Journal:  Radiat Environ Biophys       Date:  2006-10-27       Impact factor: 1.925

6.  Beneficial or deleterious effects of a preexisting hypersensitivity to bacterial components on the course and outcome of infection.

Authors:  Marina Gumenscheimer; Ivan Mitov; Chris Galanos; Marina A Freudenberg
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

Review 7.  CD14 and toll-like receptor 4: a link between infection and acute coronary events?

Authors:  R Arroyo-Espliguero; P Avanzas; S Jeffery; J C Kaski
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

8.  Haplotype variation in bovine Toll-like receptor 4 and computational prediction of a positively selected ligand-binding domain.

Authors:  Stephen N White; Kristen H Taylor; Colette A Abbey; Clare A Gill; James E Womack
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-12       Impact factor: 11.205

9.  Toll-like receptor (TLR) 4 polymorphisms are associated with a chronic course of sarcoidosis.

Authors:  S Pabst; G Baumgarten; A Stremmel; M Lennarz; P Knüfermann; A Gillissen; H Vetter; C Grohé
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

10.  CD14 and TNFα single nucleotide polymorphisms are candidates for genetic biomarkers of peri-implantitis.

Authors:  Mia Rakic; Aleksandra Petkovic-Curcin; Xavier Struillou; Smiljana Matic; Novak Stamatovic; Danilo Vojvodic
Journal:  Clin Oral Investig       Date:  2014-09-14       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.